Management Team

• Dr. Pooran Chand:
  CEO and co-founder of Therachem Research Medilab
  

Dr. Pooran Chand has an outstanding career spanning over 22 years in the field of drug discovery and medicinal chemistry mostly at BioCryst Pharmaceuticals. He is a highly accomplished scientist who discovered several drug candidates in the areas of antiviral, anticancer and cardiovascular diseases. In one of his most noted accomplishment, he has led the research team that discovered peramivir, a broad-spectrum antiviral neuraminidase inhibitor with activity against multiple strains of flu, including the H1N1 virus that causes the swine flu and H5N1 virus that causes the Asian flu.

He is also credited for the development of the first synthesis of peramivir at BioCryst. Peramivir was approved for treatment of influenza in Japan under the commercial name RAPIACTA®. Dr. Chand's vast experience and broad knowledge as a medicinal chemist as well as his hands-on management style uniquely qualify him to take on the leadership role and the supervision of projects to ensure the timely delivery and the quality of products. Dr. Chand has a very distinguished scientific track record; he is the inventor of 14 issued US patents and several pending applications. In addition he authored and co-authored 55 publications. Dr. Chand's excellence in drug discovery experience and knowledge rank him amongst the global elites in drug discovery experts and add distinction to Therachem as a company.  View CV

Dr. Ahmed Abdel-Magid:
Executive Vice President and Chief Scientific Officer of Therachem Research Medilab

Dr. Abdel-Magid joined Therachem in 2009. He worked for more than 22 years in the field of chemical process research in pharmaceutical industry at Wyeth Labs and Johnson & Johnson. He has contributed to more than 50 development projects and developed several processes that have been implemented at the industrial and manufacturing level such as Effexor (Wyeth) and Tramadol, Tepoxalin, Surfaxin & Peramivir (Johnson & Johnson). He also has a parallel academic career as adjunct professor of chemistry at Drexel University for 24 years.

He is the inventor of 21 issued US patents and several pending applications, editor of 3 books and the author of 36 publications. He is known for the development of the widely used and highly cited procedure for the reductive amination of ketones and aldehydes with sodium tricetoxyborohydride.

Dr. Abdel-Magid has served as the executive officer of the 39th National Organic Chemistry Symposium (NOS) in 2005. He is currently the National Program Chair and a member of the Executive Committee of the Division of Organic Chemistry of the American Chemical Society. He was awarded the Philip B. Hofmann Award from Johnson and Johnson (1994), the Philadelphia Organic Chemists' Club Award (2007) and was elected as a Fellow of the American Chemical Society (2009).

Dr. Abdel-Magid is a leader in process chemistry research with experience that can only be found in the top pharmaceutical organizations; he adds value and expertise to Therachem leadership team.
 View CV